JP5722627B2 - ＦＣガンマ受容体−ＩｇＧ複合体の解離、ならびにＩｇＧの精製および検出のための方法およびキット - Google Patents

ＦＣガンマ受容体−ＩｇＧ複合体の解離、ならびにＩｇＧの精製および検出のための方法およびキット Download PDF

Info

Publication number
JP5722627B2
JP5722627B2 JP2010524397A JP2010524397A JP5722627B2 JP 5722627 B2 JP5722627 B2 JP 5722627B2 JP 2010524397 A JP2010524397 A JP 2010524397A JP 2010524397 A JP2010524397 A JP 2010524397A JP 5722627 B2 JP5722627 B2 JP 5722627B2
Authority
JP
Japan
Prior art keywords
igg
endos
polypeptide
sample
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010524397A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010538623A5 (enExample
JP2010538623A (ja
Inventor
オールホーン，マリア
オリン，アンダーズ
ニメルジャーン，ファルク
コリン，マティアス
Original Assignee
ジェノビス エービー
ジェノビス エービー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェノビス エービー, ジェノビス エービー filed Critical ジェノビス エービー
Publication of JP2010538623A publication Critical patent/JP2010538623A/ja
Publication of JP2010538623A5 publication Critical patent/JP2010538623A5/ja
Application granted granted Critical
Publication of JP5722627B2 publication Critical patent/JP5722627B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/641—Cysteine endopeptidases (3.4.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01096—Mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase (3.2.1.96)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2010524397A 2007-09-14 2008-09-11 ＦＣガンマ受容体−ＩｇＧ複合体の解離、ならびにＩｇＧの精製および検出のための方法およびキット Expired - Fee Related JP5722627B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96008707P 2007-09-14 2007-09-14
US60/960,087 2007-09-14
PCT/EP2008/007457 WO2009033670A2 (en) 2007-09-14 2008-09-11 Method and kits for dissociating fcgamma-receptor-igg complexes and for igg purification and detection

Publications (3)

Publication Number Publication Date
JP2010538623A JP2010538623A (ja) 2010-12-16
JP2010538623A5 JP2010538623A5 (enExample) 2011-10-27
JP5722627B2 true JP5722627B2 (ja) 2015-05-27

Family

ID=40076765

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010524397A Expired - Fee Related JP5722627B2 (ja) 2007-09-14 2008-09-11 ＦＣガンマ受容体−ＩｇＧ複合体の解離、ならびにＩｇＧの精製および検出のための方法およびキット

Country Status (7)

Country Link
US (1) US8323908B2 (enExample)
EP (1) EP2190984B1 (enExample)
JP (1) JP5722627B2 (enExample)
CN (2) CN102584989B (enExample)
DK (1) DK2190984T3 (enExample)
PL (1) PL2190984T3 (enExample)
WO (1) WO2009033670A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002216863B8 (en) * 2000-12-21 2008-03-20 Id Biomedical Corporation Streptococcus pyogenes antigens and corresponding DNA fragments
US20120196310A1 (en) 2009-10-02 2012-08-02 Christiane Jaeger A-fucosylation detection in antibodies
WO2011059385A1 (en) * 2009-11-13 2011-05-19 Bengt Guss Immunizing composition for reducing streptococcal infections
WO2011149419A1 (en) 2010-05-26 2011-12-01 Intervacc Ab Vaccine against streptococcal infections based on recombinant proteins
GB201103780D0 (en) * 2011-03-04 2011-04-20 Hansa Medical Ab Treatment for ige-mediated disease
GB201115841D0 (en) * 2011-09-13 2011-10-26 Genovis Ab Protein and method
GB201201314D0 (en) * 2012-01-26 2012-03-07 Isis Innovation Composition
IN2014DN06806A (enExample) * 2012-02-10 2015-05-22 Univ Maryland
TW201404784A (zh) * 2012-07-27 2014-02-01 Univ Nat Chiao Tung 純化蛋白質的方法
PL2991683T3 (pl) 2013-05-02 2020-03-31 Glykos Finland Oy Koniugaty glikoproteiny lub glikanu z toksycznym ładunkiem
EP3160513B1 (en) 2014-06-30 2020-02-12 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
GB201413240D0 (en) * 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201416849D0 (en) * 2014-09-24 2014-11-05 Genovis Ab Method
GB201502306D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
CN108026518B (zh) * 2015-07-16 2022-09-06 第一三共株式会社 新型endos突变型酶
CN105368808B (zh) * 2015-11-30 2019-04-30 苏州康聚生物科技有限公司 一种IdeS蛋白酶、其制备方法及应用
CN105368904A (zh) * 2015-11-30 2016-03-02 苏州康聚生物科技有限公司 一种免疫球蛋白g片段的制备方法及应用
AU2017214441B2 (en) 2016-02-04 2021-08-19 Genovis Ab New Streptococcal proteases
AU2017360807B2 (en) * 2016-11-18 2024-11-28 Biocon Limited Rapid and efficient de-glycosylation of glycoproteins
CN110031632A (zh) * 2019-04-03 2019-07-19 中国医学科学院北京协和医院 一种反映IgG4相关性疾病的疾病活动性的生物标志物及其用途
GB202002072D0 (en) * 2020-02-14 2020-04-01 Hansa Biopharma AB immunoglobulin detection and associated therapies
GB202007431D0 (en) 2020-05-19 2020-07-01 Hansa Biopharma AB Cysteine protease
CN111707835B (zh) * 2020-07-01 2022-11-11 珠海丽珠试剂股份有限公司 用于检测IgG4的组合物、试剂盒、应用及检测方法
CA3195177A1 (en) 2020-10-07 2022-04-14 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy disorders including limb girdle 2i (lgmd2i)
WO2022221529A1 (en) 2021-04-16 2022-10-20 Asklepios Biopharmaceutical, Inc. Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response
EP4079848A1 (en) 2021-04-22 2022-10-26 Genovis Ab Immunoglobulin cleaving enzyme
WO2024057095A1 (en) 2022-09-14 2024-03-21 Genovis Ab Mutant protease
CN115873833B (zh) * 2022-11-08 2024-08-16 上海泰昶生物技术有限公司 生产免疫球蛋白g降解酶的工程菌株和工艺
WO2025256977A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Novel igm and igg cleaving enzymes
WO2025256978A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Variants of igm and igg cleaving enzymes
GB202413764D0 (en) 2024-09-18 2024-10-30 Genovis Ab Immunoglobulin proteases and their uses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9002212D0 (sv) * 1990-06-21 1990-06-21 Hightech Receptor Ab Igg binding protein
GB0130228D0 (en) * 2001-12-18 2002-02-06 Hansa Medica Ab Protein

Also Published As

Publication number Publication date
DK2190984T3 (da) 2013-12-02
US8323908B2 (en) 2012-12-04
US20100317083A1 (en) 2010-12-16
WO2009033670A2 (en) 2009-03-19
CN102584989B (zh) 2015-05-13
EP2190984B1 (en) 2013-09-04
WO2009033670A8 (en) 2009-07-09
JP2010538623A (ja) 2010-12-16
WO2009033670A3 (en) 2009-04-30
CN102584989A (zh) 2012-07-18
CN101889082A (zh) 2010-11-17
EP2190984A2 (en) 2010-06-02
PL2190984T3 (pl) 2014-02-28

Similar Documents

Publication Publication Date Title
JP5722627B2 (ja) ＦＣガンマ受容体−ＩｇＧ複合体の解離、ならびにＩｇＧの精製および検出のための方法およびキット
JP6076349B2 (ja) ストレプトコッカス・ピオゲネス由来のエンドグリコシダーゼ及びその使用方法
JP2020171320A (ja) Ｂａｃｔｅｒｏｉｄｅｓ由来のフコシダーゼおよびそれを使用する方法
Gelius et al. A mammalian peptidoglycan recognition protein with N-acetylmuramoyl-L-alanine amidase activity
KR101924673B1 (ko) 미분화 세포 검출 방법 및 복합 당질 검출 방법
Sjögren et al. On enzymatic remodeling of IgG glycosylation; unique tools with broad applications
Mathew et al. Role of Streptococcus pneumoniae extracellular glycosidases in immune evasion
JP2002515724A (ja) ヒト血清中に見出されたジペプチジルペプチダーゼｉｖ（ｃｄ２６）の新規形態、その抗体および利用法
JP2023103233A (ja) Ｏ－糖タンパク質のためのプロテアーゼ及び結合ポリペプチド
Quintana et al. The impact of glycosylation on the structure, function, and interactions of CD14
CN107208128A (zh) 用于分析抗体样本中的聚集体的方法
Girija et al. Carbohydrate recognition and complement activation by rat ficolin‐B
CN116286754B (zh) 甘露聚糖结合型丝氨酸蛋白酶同系物及其制备方法和应用
NZ622172B2 (en) Endoglycosidase from streptococcus pyogenes and methods using it
Alashaikh The Effects of Different Endoglycosidases on Erythrocyte CD44, CD47 and CD147 Purified by Affinity Chromatography

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131202

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140812

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141031

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150113

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150303

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150326

R150 Certificate of patent or registration of utility model

Ref document number: 5722627

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees